RNA
Avidity Biosciences, Inc. [RNA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RNA Stock Summary
Top 10 Correlated ETFs
RNA
Top 10 Correlated Stocks
RNA
In the News
RNA Financial details
Company Rating
-
Market Cap
1.92B
Income
-207.02M
Revenue
9.56M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
253
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-4.37
Forward P/E
-
PEG
3.45
P/S
83.78
P/B
1.64
P/C
-
P/FCF
-4.74
Quick Ratio
11.14
Current Ratio
11.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.83
EPS next Y
-
EPS next Q
-
EPS this Y
-10.19%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
27.61%
Revenue last 5Y
32.75%
Revenue Q/Q
-22.18%
EPS Q/Q
11.27%
-
-
-
-
SMA20
3.33%
SMA50
6.9%
SMA100
-31.11%
Inst Own
-
Inst Trans
-
ROA
-34%
ROE
-35%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-2144%
Profit Margin
-1917%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.825-27.66
52W High
+0.39%
52W Low
+577.63%
RSI
38
Rel Volume
1.34
Avg Volume
1.19M
Volume
1.6M
Perf Week
-15.56%
Perf Month
-16.68%
Perf Quarter
-40.77%
Perf Half Y
-35.97%
-
-
-
-
Beta
0.772
-
-
Volatility
1.77%, 1.46%
Prev Close
-8.18%
Price
27.105
Change
-9.8%
Company Profile
- Volume Average 1.19M
- Market Capitalization 1.92B
- Employee 253
- CEO Ms. Sarah Boyce
- Headquarters San Diego,CA,US
- IPO Date 2020-06-12
-
Website
https://www.aviditybiosciences.com 
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
